首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1402602

正肾上腺素抑制剂市场：按应用、分销管道和地区划分

Serotonin Norepinephrine Inhibitor Market, By Application, By Distribution Channel, By Region

出版日期: 2023年12月20日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年全球正肾上腺素抑制剂市场规模将达62.9亿美元，2023年至2030年复合年增长率为4.2%。到2030年，市场规模预计将达到84.1亿美元。

报告范围		报告详情
基准年	2022年	2023年市场规模	62.9亿美元
实际资料	2018-2021	预测期	2023-2030
预测期复合年增长率	4.20%	2030年市场规模预测	84.1亿美元

图 1. 2023 年按地区分類的正肾上腺素抑制剂的全球市场占有率(%)

正肾上腺素再回收抑制剂(SNRI) 是一类常用作治疗重度忧郁症(MDD) 和其他情绪障碍的抗忧郁症药物的药物。 SNRIs 透过抑制血清素和去甲肾上腺素（大脑中两种重要的神经传导物质）的再摄取来发挥作用。透过抑制这些神经传导物质再摄取（再摄取）到神经元中，SNRI 可以增加大脑中血清素和正肾上腺素的浓度并增强其作用。血清素与情绪、情绪和睡眠有关。去甲肾上腺素与警觉性和精力有关。增加这些神经传导物质的数量可以改善脑细胞之间的沟通，对情绪和情绪产生积极影响，并且对患有忧郁症的患者有益。

常用的 SNRI 处方包括：

文拉法辛（Effexor XR）
Duloxetine（Cymbalta）
Desvenlafaxine（Pristiq）
levomilnacipran（Fetzima）

SNRI 也被核准用于治疗焦虑症、纤维肌痛等慢性疼痛以及与糖尿病相关的神经病变疼痛。

市场动态：

全球忧郁症患者数量的增加是推动全球正肾上腺素抑制剂市场成长的主要因素。据世界卫生组织（WHO）称，全球超过5.0%的人口患有忧郁症。由于导致忧郁症发展的各种因素，例如增加的社会隔离和压力大的职场环境，预计这个数字在不久的将来还会增加。对有效治疗忧郁症的需求不断增长也推动了该市场的成长。 COVID-19 大流行的出现导致一些国家的失业率上升，并导致金融不稳定。结果，家庭收入减少，造成民众压力和焦虑，增加了抗忧郁症的需求。

另一方面，药物相关副作用预计将阻碍全球正肾上腺素抑制剂市场的成长。

本研究的主要特点

该报告详细分析了全球正肾上腺素抑制剂市场，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
根据公司亮点、产品系列、主要亮点、业绩和策略等参数对全球正肾上腺素抑制剂市场的主要参与者进行了分析。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
全球正肾上腺素抑制剂市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球正肾上腺素抑制剂市场的各种策略矩阵来促进他们的决策。

公司简介
- Pfizer Inc.
- Eli Lilly and Company
- Allergan Plc.
- AstraZeneca Plc.
- Forest Laboratories Inc.
- Johnson &Johnson
- Lundbeck A/S
- Merck &Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wyeth Pharmaceuticals Inc.
- Zydus Cadila Healthcare Ltd.
分析师观点

第9章章节

参考
调查方法
关于出版商

简介目录

Product Code: CMI5718

Global serotonin norepinephrine inhibitor market was valued at USD 6.29 bn in 2023 and is expected to exhibit a compounded annual growth rate (CAGR) of 4.2% from 2023 to 2030. By 2030, the market is estimated to reach USD 8.41 bn.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 6.29 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	4.20%	2030 Value Projection:	US$ 8.41 Bn

Figure 1. Global Serotonin Norepinephrine Inhibitor Market Share (%), By Region, 2023

Serotonin Norepinephrine Inhibitor Market - IMG1

A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) is a class of medications typically used as antidepressants in the treatment of major depressive disorder (MDD) and other mood disorders. SNRIs work by inhibiting the reuptake of two important neurotransmitters in the brain - serotonin and norepinephrine. By blocking the reabsorption (reuptake) of these neurotransmitters into the neurons, SNRIs increase the levels and enhance the actions of serotonin and norepinephrine in the brain. Serotonin is involved in mood, emotion, and sleep. Norepinephrine is related to alertness and energy. Increasing the amount of these neurotransmitters improves communication between the brain cells and can have a positive impact on mood and emotion, which is beneficial for patients suffering from depression.

Some commonly prescribed SNRIs include:-

Venlafaxine (Effexor XR)
Duloxetine (Cymbalta)
Desvenlafaxine (Pristiq)
Levomilnacipran (Fetzima)

SNRIs are also approved to treat other conditions such as anxiety disorders, chronic pain conditions like fibromyalgia, and neuropathic pain associated with diabetes.

Market Dynamics:

Rising number of people suffering from depression globally is a major factor driving the market growth of the global serotonin norepinephrine inhibitor market. According to World Health Organization (WHO), over 5.0% of the worldwide population suffers from depression. This number is expected to increase in the near future, due to various factors such as increasing social isolation and stressful work environment, which leads to the development of depression. The increase in the demand for effective treatment of depression is also driving the growth of this market. The emergence of COVID-19 pandemic increased the unemployment rate in several countries and has led to financial instability. This has resulted in a decrease in the household income, which is causing stress and anxiety among people which in turn is increasing the demand for antidepressant drugs.

On the other hand, side effects associated with the drugs is expected to hamper the market growth of the global serotonin norepinephrine inhibitor market.

Key features of the study:

This report provides in-depth analysis of the global serotonin norepinephrine inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global serotonin norepinephrine inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., and Zydus Cadila Healthcare Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global serotonin norepinephrine inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serotonin norepinephrine inhibitor market

Detailed Segmentation:

Global Serotonin Norepinephrine Inhibitor Market, By Application
- Depression
- Anxiety Disorders
- Chronic Pain
- Diabetic Neuropathy
- Others
Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Serotonin Norepinephrine Inhibitor Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Top Companies in the Global Serotonin Norepinephrine Inhibitor Market
- Pfizer Inc.
- Eli Lilly and Company
- Allergan Plc.
- AstraZeneca Plc.
- Forest Laboratories Inc.
- Johnson & Johnson
- Lundbeck A/S
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wyeth Pharmaceuticals Inc.
- Zydus Cadila Healthcare Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Increase prevalence of depression and anxiety disorders
Availability of new and improved drugs
- Restraints
Side effects
- Opportunities
Increasing adoption of telemedicine
Key Highlights
Regulatory Scenario
Recent trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Serotonin Norepinephrine Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Serotonin Norepinephrine Inhibitor Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Anxiety Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Chronic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Diabetic Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Serotonin Norepinephrine Inhibitor Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, For Sub-region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2019 - 2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Company Profile
- Pfizer Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Allergan Plc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- AstraZeneca Plc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Forest Laboratories Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Lundbeck A/S
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Otsuka Pharmaceutical Co., Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sun Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Takeda Pharmaceutical Company Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Torrent Pharmaceuticals Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Wyeth Pharmaceuticals Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Zydus Cadila Healthcare Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analysts' Views

9. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

正肾上腺素抑制剂市场：按应用、分销管道和地区划分